

A case-based update

"I'm swollen all over!"

Karen Binkley, MD, FRCPC

	Notes on Brent
	Age: 13 Presentation: Presents with episodes of nonerythematous, nonpruritic swelling
	√ Episodes of swelling began during infancy, but were generally mild.
	Affected regions have involved lips, tongue, face and extremities.
	√ Some episodes have been precipitated by minor trauma.
	$\sqrt{\text{Most episodes of swelling have no clear precipitant.}}$
	✓ Swelling lasts one to three days.
	\checkmark There is no residual rash, bruising or disfiguration.
	√ Episodes have become more frequent and severe over the last one to two years.
fo	√ Antihistamines appear to have no effect.
Ur	√ No history of allergic rhinoconjunctivitis or asthma.
	√ No history of food allergy and no common food precipitates any of these episodes.
	√ None of the episodes have been associated with ingestion of acetylsalicylic acid or non-steroidal anti-inflammatory drugs.
	√ Patient has never taken angiotensin-converting enzyme inhibitors.
	$\sqrt{\ }$ No family history of atopy or swelling.
_	Patient has no history or symptoms of lymphoproliferative disorder.
_	√ Past medical history is unremarkable.
\dashv	He is not taking any medications and has no known drug allergies.
-	√ Physical exam is normal.

Final diagnosis: Hereditary angioedema (new mutation) ✓ Typical episodes of angioedema (nonerythematous, nonpruritic angioedema lasting one to three days). ✓ Condition presents in infancy and worsens during puberty. √ Minor trauma the only identifiable common precipitant, although not always present. √ Other common causes of angioedema are excluded. ✓ Laryngeal and gastrointestinal tract involvement possible, although not seen in this patient to date. ✓ Absence of family history does not exclude the diagnosis; structural features of this gene make it relatively prone to new mutations so that 20% of patients represent new mutations. ✓ Diagnosis is confirmed with low-serum C1 inhibitor level and low C4 √ Treatment options include: 1. Tranexamic acid 2. Attenuated androgens 3. C1 inhibitor replacement **Q** For further information, see Bowen T, Cicardi M, Farkas H, et al: Canadian 2003 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. J Allergy Clin Immunol 2004; 114(3):629-37. **Dr. Binkley** is an assistant professor of medicine, division of clinical immunology and allergy, University of Toronto, and a staff member, St. Michael's Hospital and Sunnybrook Women's College Health Sciences Centre, Toronto, Ontario.